5150 Centre Avenue - Suite 4C Office 470
- Gene-environment interaction in cancer etiology
- cancer biomarkers
- cancer risk prediction
- dietary chemopreventive agents
- cancer epidemiology
- cancer prevention
- clinical trials
Dr. Yuan is a cancer epidemiologist with extensive experience in research on cancer etiology and prevention. Dr. Yuan is Principal Investigator of the Shanghai Cohort Study and the Singapore Chinese Health Study, two population-based prospective cohorts of more than 80,000 Chinese men and women with available baseline blood and urine samples with more than 25 years of active follow-up for cancer and other major health outcomes.
Utilizing these two large cohort resources coupled with a biomarker approach, Dr. Yuan and his research team have made several noteworthy contributions to the field of cancer epidemiology including (1) dietary aflatoxins as human hepatocarcinogens, (2) dietary isothiocyanates, a group of phytochemicals found in cruciferous vegetables, as potential chemopreventive agents against lung cancer development, and (3) urinary biomarkers of nicotine, tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons as risk predictors for lung cancer in smokers.
Dr. Yuan also has extensive experience in designing and conducting randomized, double-blind intervention studies on cancer prevention. Dr. Yuan is leading the effort to conduct a randomized, double-blind phase II clinical trial to evaluate the effectiveness of dietary 2-phenethyl isothiocyanates (PEITC) supplementation on reduction of risk markers for lung cancer in smokers. In addition, Dr. Yuan, collaborating with Dr. Mindy Kurzer, his former colleague at the University of Minnesota, is conducting a randomized, double-blind phase II clinical trial to evaluate the efficacy of oral supplementation of green tea extracts (Polyphenon E) on reduction of risk markers for breast cancer in women.
300 Halket St.
- Risk assessment and breast density
- Supplemental screening for breast cancer based on risk
- Comparative effectiveness of new technologies in breast imaging
- Shear wave elastography to reduce false positives on screening breast ultrasound
- Correlation of shear wave elastography with prognostic factors and treatment response
- Comparison of tomosynthesis and ultrasound for cancer detection
- Comparison of molecular breast imaging and MRI for contralateral screening in women with newly diagnosed breast cancer
5200 Centre Avenue, Suite 409
- Hereditary pancreatic cancer
- early detection of pancreatic cancer
- colon cancer
- Breast cancer
- sex hormones
5117 Centre Ave
My training is in molecular cancer and environmental epidemiology. Through my doctoral and postdoctoral research, I developed skills in advanced statistical analysis and programming, genetics, epigenomics, and cancer registry analysis. Given my data science skills and ability to translate data results to practice (e.g. grants, research directions, clinic), I was hired to serve as collaborator and resource for HCC investigators and as bridge between the epidemiology and biostatistics groups at HCC. My research interests focus on 1) utilizing cancer registry data to explore socio-economic, racial, and environmental disparities in cancer incidence and mortality and 2) exploring the interplay among toxicants, aging, and dynamic genomic features (e.g., telomeres, DNA methylation and somatic mutations) and the effect of this interplay on cancer development and prognosis. My current research profile at HCC includes characterizing cancer incidence, mortality, and survival disparities and trends in western PA, examining radon and fracking exposures on cancer risk in PA, and evaluating genetic predictors associated with head and neck cancer survival. I plan to become more involved in projects related to environmental somatic mutational signatures in cancer, DNA methylation biomarkers in cancer detection, risk, and prognosis, and other epigenomic and genomic studies of cancer risk and survival.
5150 Centre Ave, Suite 4C
- Molecular epidemiology
- cancer epidemiology
- genetic variation
- cancer prevention
- lung cancer
- head and neck cancer
Dr. Diergaarde's research examines the role of diet, lifestyle and genetic variation in the development, progression and treatment of cancer, including cancers of the lung, head and neck, colon, ovaries and breast, and aims to identify markers for risk stratification, early detection and response to treatment. She is currently Co-Leader of Project 2 of the UPCI Specialized Program of Research Excellence (SPORE) in Lung Cancer. This project seeks to establish the relationship between vitamin D exposure, pulmonary inflammation and lung cancer risk and so provide strong rationale for a vitamin D-based approach to lung cancer prevention. She is also Leader of Project 1 of the UPCI SPORE in Head and Neck Cancer. Using data and samples from a large, clinic-based case-control study, this project investigates the role of genetic variation and gene-environment interactions in the development, progression and treatment of head and neck squamous cell carcinoma.
Fifth Floor, Suite 500.68
- early detection
5607 Baum Boulevard
My cancer research interests focus on the development of tools designed to make information more useful for translational researchers. Since 2014, I have been a co-investigator and then MPI (with Guergana Savova of Boston Children’s Hospital and Jeremy Warner of Vanderbilt University) on an NCIfunded project “Cancer Deep Phenotyping from Electronic Medical Records”(U24 CA248010-01A1). Known as “DeepPhe”, this project is aimed at extracting longitudinal patient histories from clinical notes via Natural Language Processing and developing visual analytics tools that will facilitate the use of this data for cohort discovery. My role in this effort has been to lead qualitative inquiries into clinician information needs and goals, as needed to guide the design of interactive tools. With additional NCI funding starting in 2019, and with the added collaboration of Eric Durbin of the University of Kentucky/Kentucky Cancer registry, we are working to adapt these tools to facilitate cancer registry data abstraction processes (UG3 CA243120-02).
- Protein kinases and phosphatases
- post-translational modifications
- histone deacetylases
- cancer biology
130 DeSoto Street
Prior to joining Pitt GSPH I served as the Associate Director for Population Sciences of the Tulane University Cancer Center for 15 years. I also represented Tulane on the NCI GMAP region 2 consortium. My cancer-related research focuses on cancer health disparities locally and globally with a special emphasis on the Caribbean. Of special interest is the role exposures to chemicals and non-chemicals stressors play in cancer development.
200 Lothrop Street
- Early detection and prevention of colorectal cancer (CRC)
- flexible sigmoidoscopy
- acceptability and implementation of CRC screening
- surveillance colonoscopy
- relationship of insulin/insulin-like growth factors to adenomatous polyps and CRC
5117 Centre Ave
- Cancer pharmacology
- drug discovery
- dietary anti-cancer compounds
- withaferin A
- cancer prevention
The primary research interests of the Singh laboratory include molecular characterization of novel cancer chemopreventive agents and rational design of mechanism-driven combination chemoprevention regimens. Cellular and transgenic animal models are used to screen potential cancer chemopreventive constituents from dietary and medicinal plants. Cutting edge cellular, molecular biological, omics (metabolomics and proteomics), structural biology, and imaging techniques (MRI and bioluminescence) are used to (a) determine the mechanism of action of promising cancer chemopreventive agents, (b) monitor effects on cancer progression, and (c) identify biomarkers predictive of tissue exposure and possibly response. Some of the agents under active investigation in the Singh laboratory include: cruciferous vegetable-derived isothiocyanates, garlic-derived organosulides, and medicinal plant constituent withaferin A. As an example, recent published work from the Singh laboratory indicates suppression of glycolysis in mammary cancer prevention by withaferin A in a transgenic mouse model. Likewise, complementary cellular and molecular biological, targeted proteomics, and molecular modeling techniques were used to identify beta-tubulin as a novel target of cancer cell growth arrest by withaferin A (WA).
- Environmental epidemiology
C-Wing-PUH 200 Lothrop Street
- Mechanisms of complex disorders including acute pancreatitis, chronic pancreatitis, and pancreatic cancer
- Lung cancer screening, chemoprevention, diagnosis, staging and treatment
- pulmonary medicine
Dr. Wilson's research interests include: lung cancer screening and chemoprevention, diagnosis, staging and treatment; COPD, especially as it relates to lung cancer; occupational lung diseases; and general pulmonary medicine.
3471 Fifth Ave, Suite 101
- Thyroid cancer
- parathyroid cancer
- molecular markers
- Genetic and molecular epidemiology